Avalo Therapeutics
AVTXAvalo Therapeutics is a clinical-stage biotechnology company focused on the development of monoclonal antibody therapies for immune-mediated inflammatory diseases.
Earnings
Next report
Aug 6, 2026 (In 3 weeks)EPS estimate-$0.66
Financials
Q1 2026Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Avalo Therapeutics is a clinical-stage biotechnology company focused on the development of monoclonal antibody therapies for immune-mediated inflammatory diseases. The company's primary value proposition centers on targeting the IL-1β pathway to address prevalent indications with significant unmet medical needs.
Competitive position
A clinical-stage developer focused on a specific cytokine pathway (IL-1β) within the highly competitive immunology and inflammation market.
GeographiesUnited States
Customer segmentsPatients, Healthcare Providers
Business modelResearch and Development, IP Licensing
SuppliersContract Manufacturing Organizations (CMOs), Clinical Research Organizations (CROs), Specialized laboratory equipment providers
CustomersSpecialty pharmacies, Hospitals, Large pharmaceutical companies for potential out-licensing
CountryUnited States of America
Listed2015
Employees19.0
CEOGarry A. Neil
SectorHealthcare
IndustryBiotechnology
Websiteavalotx.com
FilingsSEC EDGAR
Questions, answered.
- What is Avalo Therapeutics's market cap?
- Avalo Therapeutics (AVTX) has a market capitalization of $1.0B and trades on NASDAQ.
- Who are Avalo Therapeutics's competitors?
- Avalo Therapeutics's key competitors include AbbVie, Novartis, Eli Lilly, and others. These companies compete in similar markets and product categories.
- Where is Avalo Therapeutics headquartered?
- Avalo Therapeutics is headquartered in United States of America and employs approximately 19 people. It has been publicly traded since 2015.